North American Scientific receives FDA clearance to market nomosSTAT for cancer treatment

By Lisa Kerner

Charlotte, N.C., July 24 - North American Scientific, Inc. said its Nomos Radiation Oncology division received 510(k) clearance from the Food and Drug Administration to market nomosSTAT, a new serial tomotherapy automated treatment solution.

nomosSTAT's serial tomotherapy delivery shapes and modulates the radiation beam for more flexibility in depositing the dose to the target while avoiding critical structures.

"FDA clearance of nomosSTAT marks another milestone for the company as we execute our strategy to develop advanced yet affordable technologies that enhance the radiation therapy community's ability to treat cancer more aggressively," president and chief executive officer L. Michael Cutrer said in a company news release.

"This approval further expands our ability to provide leading-edge cancer treatment technologies for individuals battling cancer and address an important market opportunity."

The company said it expects to record the first revenue from sales of nomosSTAT in the fourth quarter of its current fiscal year ending Oct. 31.

Based in Chatsworth, Calif., North American Scientific manufactures products used in oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.